The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with adaptation to high altitude: A meta-analysis

Yuxiao Wang¹,²,³, Hongxiang Lu¹,²,³, Yu Chen³ and Yongjun Luo¹,³

Abstract
Background: Fluid retention is linked to the physiology and pathophysiology of humans at high altitude (HA). The angiotensin-converting enzyme (ACE) gene plays a role in the regulation of plasma volume and vascular tone.

Materials and methods: In this meta-analysis, eligible studies published before 1 September 2015 that focused on the association between the ACE insertion/deletion (I/D) polymorphism and HA adaption were identified by searching the PubMed, Web of Science, Embase and Medline online databases. We used a fixed-effects model and assessed the study qualities multiple times.

Results: The seven selected studies included a total of 582 HA-native individuals and 497 low-altitude controls, and these subjects were analyzed for the ACE I/D gene polymorphism. A significant association was found between the ACE DD genotype and HA maladaptation. The results for genotype DD versus ID + II were as follows: Odds ratio (OR) = 0.46; 95% CI 0.31–0.70; p = 0.0002. The results for genotype ID versus DD were as follows: OR = 1.97; 95% CI 1.27–3.06; p = 0.002.

Conclusions: Our findings suggested that the DD genotype of ACE is a risk factor for HA maladaptation and that the presence of fewer ACE DD allele carriers in a population indicates a greater ability of that population to adapt to HA.

Keywords
Adaptation, altitude, altitude disorders, altitude sickness, angiotensin-converting enzyme, deletion, genotype, hypoxia, insertion, high-altitude, meta-analysis, oxygen absorption, polymorphism

Date received: 25 June 2015; accepted: 22 December 2015

Introduction
Approximately 140 million people live at altitudes > 2500 m above sea level.¹ These high altitude (HA) areas have been inhabited for several thousand years²; and unlike individuals living at lower altitudes, the natives or inhabitants are better adapted to HA. In the last decade, a significant number of studies have investigated HA adaptation and disorders³,⁴ and whether HA populations have undergone natural selection for features beneficial to the absorption and utilization of oxygen. Some reviews have explored HA adaptation in relation to genetics.²,⁵,⁶ Previous studies report that HA adaptation may be associated with certain genes, including several found in mitochondrial deoxyribonucleic acid (mtDNA)⁵,⁷,⁸; and the genes encoding endothelial Per-Arnt-Sim (EPAS)¹,⁸,¹⁰ erythropoietin (EPO),¹¹,¹² myoglobin,¹³ hypoxia-inducible factor 1 (HIF1),¹⁴ angiotensin-I converting enzyme (ACE),¹⁵–¹⁷ aldosterone synthase (CYP11B2),¹⁸ nitric oxide synthase 3 (NOS3), endothelin 1 (EDN1)¹⁹,²⁰ and beta-2 adrenergic receptor (ADRB2).²¹

ACE is a particular key component of the renin-angiotensin-aldosterone system (RAAS); and it plays important
roles in the physiology and pathophysiology of humans living at HA, and the pathogenesis of HA sickness: These roles of ACE are most likely achieved through its effects on the regulation of blood pressure, through the generation of the potent vasoconstrictor angiotensin II (AngII) and through the blockade of the production of the vasodilator bradykinin. In addition, studies report that ACE activity may contribute to adaptive physiology by affecting the adaptive respiratory response in hypoxic conditions, by influencing the normalization of pulmonary artery pressure, and the maintenance of sodium and fluid balances.

An ACE polymorphism has been described that involves the insertion (I)/deletion (D) of a 287-base pair (bp) Alu repeat element in intron 16, which is a marker of the ACE functional polymorphism. Montgomery et al. hypothesized that the D allele is associated with altered levels of serum ACE. Droma et al. reported that the over-representation of the I allele of the ACE gene in Sherpas might have an advantageous physiological role in adapting to a high-altitude environment. In addition, several investigations have focused on the relationship of the ACE gene I/D polymorphism with the human adaptation to HA. Qadar et al. report that the genotype II may play a beneficial physiological role in HA adaptation; and that the I allele may contribute to routine physical activities, by aiding in adaptation to the hypoxic environment at HA. We performed this meta-analysis to investigate whether an association exists between the ACE gene I/D polymorphism and HA adaptation in native HA inhabitants.

Materials and methods

Literature search

We searched the literature published before 1 September 2015 in the following databases: PubMed, Embase, Web of Science and Medline. We performed an advanced search using several search options. The following keywords were used: angiotensin-convert enzyme or ACE, high altitude or HA, adaptation and polymorphism. We examined the bibliographies of the included papers. The articles were limited to those written in English. This study was approved by the Ethical Committee of the Third Military Medical University in China.

Inclusion and exclusion criteria

Studies with the following criteria were included in the meta-analysis:

- The provision of sufficient data to analyze the results; and
- The inclusion of control data that was in agreement with Hardy-Weinberg equilibrium.

Studies with the following characteristics were excluded from the meta-analysis:

- Presence of HA diseases;
- Lack of information regarding genotype number or frequency;
- Lack of comparisons between high- and low-altitude subjects or the inclusion of comparisons of identical subjects at low and high altitudes; and
- Inclusion of control data that was not in accordance with Hardy-Weinberg equilibrium.

Data extraction

The following characteristics were recorded for each study: first author, year of publication, study ethnicities or areas, study population and ACE I/D genotypes of the cases and controls. All cases were permanent residents and were members of families that had resided in the HA area since ancient times and had acclimated to HA.

Statistical analysis

In this meta-analysis, we evaluated the associations between the I/D alleles of the ACE gene and HA adaptation, using the following four comparisons:

1. An allelic comparison (D versus I);
2. Comparison of the DD homozygous genotype to the other genotypes (DD versus ID + II and DD versus II);
3. Comparison of the ID heterozygous genotype to the other genotypes (ID versus DD and ID versus II); and
4. Comparison of the II homozygous genotype to the other genotypes (II versus DD + ID).

We used the odds ratio (OR) as a measure of the strength of the associations between polymorphisms of the ACE I/D gene and HA adaptation risk across studies. We compared the frequencies of the alleles and genotypes between the cases and controls, using the unadjusted OR and the relevant 95% CI. We also used the chi-square-based Q test and I² test, to evaluate heterogeneity among the studies. If there was significant heterogeneity (p < 0.05), we used a random-effects model to calculate the pooled OR of each study. If there was no heterogeneity (p > 0.05), the pooled OR was calculated using the fixed-effects model. The Bonferroni correction was used to adjust for multiple hypothesis testing; and p < 0.008 was considered to be
Wang et al.

statistically significant. We also used Begg’s test and Egger’s test to evaluate potential publication bias, which was considered to be significant at $p < 0.05$. All analyses were performed with RevMan 5.0 software (The Cochrane Collaboration) according to Qi et al.39

Results

Study characteristics

We identified 96 reports using the keywords “angiotensin-converting enzyme” and “altitude”. We excluded 90 reports by applying our inclusion and exclusion criteria. Among the 90 excluded reports, 38 did not include information about the ACE I/D gene polymorphism, seven included HA diseases, and 45 of these reports did not compare high- and low-altitude subjects. Finally, for this meta-analysis, we selected seven studies (of note, the report by Rupert et al.40 provided two sets of data; therefore, we considered these to be two independent studies) with 582 HA cases and 497 low-altitude controls. In Table 1, we present the characteristics of the studies that evaluated the associations between the ACE I/D polymorphism and HA adaptation. Three studies examined Quechua populations; and the remaining studies focused on Sherpa, Tibetan, Peruvian and Indian populations. The sample sizes of these studies ranged from 92 to 257 subjects.

Meta-analysis results

The summary OR, which was obtained using a random effects model, did not reveal a significant difference in HA adaptation between carriers of the ACE D and I alleles (Table 2) (OR = 0.70; 95% CI 0.49–1.02; $p = 0.06$) (Figure 1); however, the summary OR of the fixed-effects model showed a significant difference in HA adaptation between the DD and ID + II genotypes (OR = 0.46; 95% CI 0.31–0.70; $p = 0.0002$) (Figure 2). Furthermore, the summary OR obtained using a random-effects model with Bonferroni correction did not reveal a significant difference in HA adaptation between the DD and II genotypes (OR = 0.39; 95% CI 0.18–0.84; $p = 0.02$) (Figure 3). In addition, no significant difference in HA adaptation was observed between the DD + ID and II genotypes (OR = 1.41; 95% CI 0.87–2.29; $p = 0.16$) (Figure 4); however, a significant difference in HA adaptation was found between the DD and ID genotypes (OR = 1.97; 95% CI 1.27–3.06; $p = 0.002$) (Figure 5). Finally, no significant difference in HA adaptation was observed between the DD and II genotypes (OR = 0.80; 95% CI 0.51–1.26; $p = 0.33$) (Figure 6).

Discussion

To our knowledge, this is the first meta-analysis to evaluate the association of the ACE gene I/D polymorphism with HA adaptation. Seven studies with a total of 582 native HA inhabitants and 497 native low altitude inhabitants were included in this meta-analysis. No significant difference in HA adaptation was found between the ACE D allele and the I allele ($p < 0.05$). For the comparison of the DD versus the ID + II genotypes, the OR = 0.46; and for the comparison of the ID versus the DD genotypes, the OR = 1.97; 95% CI 1.27–3.06; $p = 0.002$ (Figure 5). Finally, no significant difference in HA adaptation was observed between the ID and II genotypes (OR = 0.80; 95% CI 0.51–1.26; $p = 0.33$) (Figure 6).

In support of our meta-analysis results, the following factors may explain why the DD genotype is a risk factor for HA maladaptation. First, ACE polymorphisms affect circulating ACE activity.41–44 Mean plasma ACE levels in

| First author | Publication year | Origin | Origin | Altitude (m) | Sample size | Genotypes | Genotypes |
|--------------|------------------|--------|--------|--------------|-------------|-----------|-----------|
| Buroker NE   | 2010             | Tibetan | Han    | 3600–4400 | 35          | DD 5 | 16 | HA subjects |
| Bigham AW    | 2008             | Cerro de Pasco | Barrios Altos | 4338 | 74          | ID 68 | 14 | LA subjects |
| Droma Y      | 2008             | Sherpa | Non-Sherpa | 3440 | 105         | II 111 | 6 | LA subjects |
| Rupert JL    | 2003             | Quechua | Maya | 3000–4500 | 111         | DD 5 | 5 | HA subjects |
| Qadar Pasha MA | 2001          | Ladakhi | lowlander | 3600 | 131         | ID 126 | 5 | LA subjects |
| Rupert JL    | 1999             | Quechua | Caucasian | 3200–4200 | 63          | II 34 | 2 | LA subjects |
| Rupert JL    | 1999             | Quechua | Na-Dene | 3200–4200 | 63          | DD 50 | 2 | LA subjects |

ACE: angiotensin-converting enzyme; D: deletion; I: insertion; LA: low altitude; HA: high altitude.
individuals with the DD genotype are higher than those in individuals with the II genotype, and individuals with the ID genotype have intermediate mean plasma ACE levels; therefore, we could conclude that higher ACE DD genotype might contribute to ACE activity and therefore increased the production of angiotensin II, and that the higher ACE DD genotype might increase the risk of HA maladaptation. Some studies report that subjects with the DD genotype have higher plasma angiotensin II concentrations after angiotensin I infusion, and the Type I receptor of angiotensin II was shown to initiate Ca\(^{2+}\) signaling that mediates the contraction of vascular smooth muscle cells, which can influence blood pressure. Angiotensin II also controls water and salt retention, through the release of aldosterone. High blood pressure and water and salt retention are related to the occurrence of HA diseases, so these findings suggest that a higher DD genotype frequency in a population is not beneficial to HA adaption. Lachurie et al. report that the ACE I/D polymorphism has no influence on the production of Ang II nor plasma aldosterone, and does not cause a rise in blood pressure; these findings may have been due to the lack of elimination of potential differences in Ang I conversion rates at the coronary and renal vessels. Furthermore, the ACE DD genotype was shown to be associated with increased bradykinin degradation, which is associated with significant blunting of the vasodilatory action of nitric oxide. Nitric oxide decreases the occurrence of mountain sickness, so the ACE DD genotype decreases a person’s ability to adapt to HA. In addition, reduction in ACE activity level was reported to cause an increase in Ang 1–7, which is a vasodilator. The activities of Ang 1–7 may further contribute to vasodilation, and higher Ang 1–7 production. This meta-analysis demonstrated that HA native populations have lower frequencies of the DD genotype, and that this condition aids in HA adaptation.

![Figure 1](image_url)

**Figure 1.** Forest plot of the ACE I/D polymorphism: D versus I.

The summary OR is displayed under the allelic model. The width of the 95% CI is indicated by the left and right values of the OR. The data show the adaptive abilities conferred by the ACE I allele in both the cases and controls.

ACE: angiotensin converting enzyme; D: deletion; I: insertion; M/H: Mantel Haenszel; OR: odds ratio.

### Table 2. Meta-analysis of the association of ACE I/D polymorphism with HA adaptation.

| No | Polymorphisms/ genotypes | Heterogeneity OR 95% CI | p value | Figure |
|----|---------------------------|-------------------------|---------|--------|
| 1  | D versus I                | 0.0003                  | 0.70    | 0.44–1.02 | 0.06 | 1 |
| 2  | DD versus ID + II         | 0.13                    | 0.46    | 0.31–0.70 | 0.0002 | 2 |
| 3  | DD versus II              | 0.009                   | 0.39    | 0.18–0.84 | 0.02 | 3 |
| 4  | DD + ID versus II         | 0.001                   | 1.41    | 0.87–2.29 | 0.16 | 4 |
| 5  | ID versus DD              | 0.48                    | 1.97    | 1.27–3.06 | 0.002 | 5 |
| 6  | ID versus II              | 0.03                    | 0.80    | 0.51–1.26 | 0.33 | 6 |

ACE: angiotensin-converting enzyme; D: deletion; I: insertion; No: number of polymorphisms.
frequency of the ACE DD genotype have a reduced ability to adapt to HA; however, Droma et al.\textsuperscript{34} report that different ACE haplotypes did not affect the serum level of ACE, and that the serum level of ACE was not related to the D allele in Sherpas and non-Sherpas. The ACE DD genotype is also reported to be a risk factor for many HA illnesses. For example, the frequency of the ACE D allele is higher in Han individuals with acute mountain sickness (AMS) and in Tibetan residents with chronic mountain sickness (CMS).\textsuperscript{52} Furthermore, Qi et al.\textsuperscript{39} conducted a meta-analysis of five studies and found that carriers of the ACE D allele were at significant risk for developing HAPE.

This study has several limitations. First, only a small number of qualified studies were available, which prevented us from performing subgroup analyses to identify the potential effects on HA adaptation of other factors, such as gender and age; thus, linkage disequilibrium may exist and may be responsible for the observed variations in plasma ACE level. Second, the studies included in the meta-analysis investigated subjects residing at different altitudes; therefore, we just predict a trend about ACE genotype and HA adaptation. Third, the sample size was small, mainly due to the scarcity of existing publications regarding HA adaptation. Further studies should evaluate the associations between the ACE DD genotype and HA adaptation, using larger sample sizes or other populations. Finally, we explored the association between the ACE I/D polymorphism and HA adaptation, but did not evaluate whether other ACE polymorphisms were associated with HA adaptation. Therefore, the role of the ACE I/D polymorphism may be masked by the effects of other genes or by the environment.
Figure 4. Forest plot of the ACE I/D polymorphism: DD + ID versus II.
The summary OR is displayed under the allelic model. The width of the 95% CI is indicated by the left and right values of the OR. The data show the adaptive abilities conferred by the ACE DD and ID genotypes in both the cases and controls.
ACE: angiotensin converting enzyme; D: deletion; I: insertion; M/H: Mantel Haenszel; OR: odds ratio.

Figure 5. Forest plot of the ACE I/D polymorphism: ID versus DD.
The summary OR is displayed under the allelic model. The width of the 95% CI is indicated by the left and right values of the OR. The data show the adaptive abilities conferred by the ACE ID genotype in both the cases and controls.
ACE: angiotensin converting enzyme; D: deletion; I: insertion; M/H: Mantel Haenszel; OR: odds ratio.

Figure 6. Forest plot of the ACE I/D polymorphism: ID versus II.
The summary OR is displayed under the allelic model. The width of the 95% CI is indicated by the left and right values of the OR. The data show the adaptive abilities conferred by the ACE ID genotype, both in the cases and controls.
ACE: angiotensin converting enzyme; D: deletion; I: insertion; M/H: Mantel Haenszel; OR: odds ratio.
Conclusions
In summary, we analyzed the association of an ACE polymorphism with HA adaptation. We found that the ACE DD genotype is a risk factor for HA maladaptation and that a lower frequency of the ACE DD genotype in a population indicates a greater ability of individuals in that population to adapt to HA.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (No. 81571843).

References
1. Gonzales GF, Steenland K and Tapia V. Maternal hemoglobin level and fetal outcome at low and high altitudes. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1477–1485.
2. Stobdan T, Karar J and Pasha MA. High altitude adaptation: Genetic perspectives. High Alt Med Biol 2008; 9: 140–147.
3. Lahiri S. Historical perspectives of cellular oxygen sensing and responses to hypoxia. J Appl Physiol 2000. 88: 1467–1473.
4. Semenza GL. Perspectives on oxygen sensing. Cell 1999; 98: 281–284.
5. Luo Y, Yang X and Gao Y. Mitochondrial DNA response to high altitude: A new perspective on high-altitude adaptation. Mitochondrion DNA 2013; 24: 313–319.
6. Simonson TS, Yang Y, Huff CD, et al. Genetic evidence for high-altitude adaptation in Tibet. Science 2010; 329: 72–75.
7. Ji F, Sharpley MS, Derbeneva O, et al. Mitochondrial DNA variant associated with Leber hereditary optic neuropathy and high-altitude Tibetans. Proc Natl Acad Sci USA 2012; 109: 7391–7396.
8. Luo Y, Gao W, Liu F, et al. Mitochondrial nt3010G–nt3970C haplotype is implicated in high-altitude adaptation of Tibetans. Mitochondrion DNA 2011; 22: 181–190.
9. Hochachka PW, Buck LT, Doll CJ, et al. Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 1996; 93: 9493–9498.
10. Yi X, Lian Y, Huerta-Sanchez E, et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 2012; 329: 75–78.
11. Arnaud J, Quilici JC and Riviere G. High-altitude haematology: Quechua-Aymara comparisons. Ann Hum Biol 1981; 8: 573–578.
12. Ge RL, Witkowski S, Zhang Y, et al. Determinants of erythropoietin release in response to short-term hypobaric hypoxia. J Appl Physiol 2002; 92: 2361–2367.
13. Gelfi C, De Palma S, Ripamonti M, et al. New aspects of altitude adaptation in Tibetans: A proteomic approach. FASEB J 2004; 18: 612–614.
14. Liu KX, Sun XC, Wang SW, et al. [Association of polymorphisms of 1772 (C→T) and 1790 (G→A) in HIF1A gene with hypoxia adaptation in high altitude in Sherpas]. 2007. 24: 230–232.
15. Myerson S, Hemingway H, Budget R, et al. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol 1999; 87: 313–316.
16. Qadar Pasha MA, Khan AP, Kumar R, et al. Angiotensin converting enzyme insertion allele in relation to high-altitude adaptation. Ann Hum Genet 2001; 65: 531–536.
17. Rupert JL, Kidd KK, Norman LE, et al. Genetic polymorphisms in the renin-angiotensin system in high-altitude and low-altitude Native American populations. Ann Hum Genet 2003; 67: 17–25.
18. Rajput C, Arif E, Vibhuti A, et al. Predominance of interaction among wild-type alleles of CYP11B2 in Himalayan natives associates with high-altitude adaptation. Biochem Biophys Res Commun 2006; 348: 735–740.
19. Morganti A, Giussani M, Sala C, Giussani M, et al. Effects of exposure to high altitude on plasma endothelin-1 levels in normal subjects. J Hypertens 1995; 13: 859–865.
20. Rajput C, Najib S, Norboo T, et al. Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in high-altitude natives. Biochem Biophys Res Commun 2006; 341: 218–224.
21. Mazzeo RS and Reeves JT. Adrenergic contribution during acclimatization to high altitude: Perspectives from Pikes Peak. Exerc Sport Sci Rev 2003; 31: 13–18.
22. Wang QQ, Yu L, Huang GR, et al. Polymorphisms of angiotensin converting enzyme and nitric oxide synthase 3 genes as risk factors of high-altitude pulmonary edema: A case-control study and meta-analysis. Tohoku J Exp Med 2013; 229: 255–266.
23. Woods DR and Montgomery HE. Angiotensin-converting enzyme and genetics at high altitude. High Alt Med Biol 2001; 2: 201–210.
24. Luo Y, Chen Y, Zhang Y, et al. The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with acute mountain sickness susceptibility: A meta-analysis. High Alt Med Biol 2012; 13: 252–257.
25. Milledge JS and Catley DM. Angiotensin-converting enzyme activity and hypoxia. Clin Sci 1987; 72: 149.
26. Morrell NW, Sarybaev AS, Alikhan A, et al. ACE genotype and risk of high-altitude pulmonary hypertension in Kyrgyz highlanders. Lancet 1999; 353: 814.
27. Muller DN, Bohlender J, Hilgers KF, et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997; 29: 98–104.
28. Patel S, Woods DR, Macleod NJ, et al. Angiotensin-converting enzyme genotype and the ventilatory response to exertional hypoxia. Eur Respir J 2003; 22: 755–760.
29. Santolaya RB, Lahiri S, Alfaro RT, et al. Respiratory adaptation in the highest inhabitants and highest Sherpa mountaineers. Respir Physiol 1989; 77: 253–262.
30. Kumar R, Pasha Q, Khan AP, et al. Renin angiotensin aldosterone system and ACE I/D gene polymorphism in high-altitude pulmonary edema. Aviat Space Environ Med 2004; 75: 981–983.
31. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990; 86: 1343–1346.

32. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE polymorphisms. *Circ Res* 2006; 98: 1123–1133.

33. Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. *Circulation* 1997; 96: 741–747.

34. Droma Y, Hanaoka M, Basnyat B, et al. Adaptation to high altitude in Sherpas: Association with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. *Wilderness Environ Med* 2008; 19: 22–29.

35. Qadar Pasha MA, Khan AP, Kumar R, et al. Angiotensin converting enzyme insertion allele in relation to high altitude adaptation. *Ann Hum Genet* 2001; 65: 531–536.

36. Luo Y, Chen Y, Zhang Y, et al. Association of endothelial nitric oxide synthase (eNOS) G894T polymorphism with high altitude pulmonary edema susceptibility: A meta-analysis. *Wilderness Environ Med* 2012; 23: 270–274.

37. Ma X, Chen C, Xia H, et al. Transforming growth factor beta 1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: Evidence from 10,392 cases and 11,697 controls. *Breast Cancer Res Treat* 2010; 124: 453–457.

38. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; 22: 719–748.

39. Qi Y, Sun J, Zhu T, et al. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with high-altitude pulmonary oedema: A meta-analysis. *J Renin Angiotensin Aldosterone Syst* 2011; 12: 617–623.

40. Rupert JL, Devine DV, Monsalve MV, et al. Angiotensin-converting enzyme (ACE) alleles in the Quechua, a high altitude South American native population. *Ann Hum Biol* 1999; 26: 375–380.

41. Costerousse O, Allegreni J, Lopez M, et al. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. *Biochem J* 1993; 290: 33–40.

42. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. *Circulation* 1995; 92: 1387–1388.

43. Davis GK, Millner RW and Roberts DH. Angiotensin-converting enzyme (ACE) gene expression in the human left ventricle: Effect of ACE gene insertion/deletion polymorphism and left ventricular function. *Eur J Heart Fail* 2000; 2: 253–256.

44. Mizuiri S, Hemmi H, Kumanomidou H, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. *Kidney Int* 2001; 60: 1124–1130.

45. Brown NJ, Blais C Jr, Gandhi SK, et al. ACE insertion/deletion genotype affects bradykinin metabolism. *J Cardiovasc Pharmacol* 1998; 32: 373–377.

46. Ueda S, Elliott HL, Morton JJ, et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. *Hypertension* 1995; 25: 1266–1269.

47. Luo Y, Zou Y and Gao Y. Gene polymorphisms and high-altitude pulmonary edema susceptibility: A 2011 update. *Respiration* 2012; 84: 155–162.

48. Lachurie ML, Azizi M, Goyene TT, et al. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. *Circulation* 1995; 91: 2933–2942.

49. Butler R, Morris AD, Burchell B, et al. DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. *Hypertension* 1999; 33: 1164–1168.

50. Ferrario CM and Iyer SN. Angiotensin-(1–7): A bioactive fragment of the renin-angiotensin system. *Regul Pept* 1998; 78: 13–18.

51. Woods D. Angiotensin-converting enzyme, renin-angiotensin system and human performance. *Med Sport Sci* 2009; 54: 72–87.

52. Buroker NE, Ning XH, Zhou ZN, et al. Genetic associations with mountain sickness in Han and Tibetan residents at the Qinghai-Tibetan Plateau. *Clin Chim Acta* 2010; 411: 1466–1473.